CALCA and migraine disorder: Although neither guideline directly references adequate trial or discontinuation recommendations for oral small-molecule CGRP receptor antagonists (gepants) [11, 24], both emphasize the improved tolerability of CGRP-targeted preventive migraine therapies over traditional nonspecific oral therapies (e.g., beta-blockers, calcium-channel blockers, and anti-depressants) [11, 23, 25].